Cargando…
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
Sequencing of cell-free DNA (cfDNA) in cancer patients’ plasma offers a minimally-invasive solution to detect tumor cell genomic alterations to aid real-time clinical decision-making. The reliability of copy number detection decreases at lower cfDNA tumor fractions, limiting utility at earlier stage...
Autores principales: | Orlando, Francesco, Romanel, Alessandro, Trujillo, Blanca, Sigouros, Michael, Wetterskog, Daniel, Quaini, Orsetta, Leone, Gianmarco, Xiang, Jenny Z, Wingate, Anna, Tagawa, Scott, Jayaram, Anuradha, Linch, Mark, Jamal-Hanjani, Mariam, Swanton, Charles, Rubin, Mark A, Wyatt, Alexander W, Beltran, Himisha, Attard, Gerhardt, Demichelis, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154344/ https://www.ncbi.nlm.nih.gov/pubmed/35664542 http://dx.doi.org/10.1093/narcan/zcac016 |
Ejemplares similares
-
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
por: Hasan, A. M. Mahedi, et al.
Publicado: (2023) -
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2020) -
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
por: González-Billalabeitia, Enrique, et al.
Publicado: (2018) -
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges
por: Trujillo, Blanca, et al.
Publicado: (2022) -
Identification of single nucleotide variants using position-specific error estimation in deep sequencing data
por: Kleftogiannis, Dimitrios, et al.
Publicado: (2019)